FDA-cleared profile

Annalise Enterprise

Annalise-AI · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: Triage and prioritization of adult CXR and non-contrast brain CT studies for specified suspected findings, including pneumoperitoneum, pleural effusion, pneumothorax and tension pneumothorax on CXR, and acute extra-axial hemorrhage, subarachnoid hemorrhage, intra-axial hemorrhage, intraventricular hemorrhage, mass effect, obstructive hydrocephalus and vasogenic edema on brain CT.

Clinical role
Notification-only study triage and prioritization; the product is not a standalone clinical decision tool or a rule-out system.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Chest/Lung; Brain
Key limitation
Keep in mind: Cleared adult use is limited to the listed findings and input requirements. Notifications do not replace image interpretation, are not a standalone clinical decision, and should not be treated as a negative rule-out result.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Triage and prioritization of adult CXR and non-contrast brain CT studies for specified suspected findings, including pneumoperitoneum, pleural effusion, pneumothorax and tension pneumothorax on CXR, and acute extra-axial hemorrhage, subarachnoid hemorrhage, intra-axial hemorrhage, intraventricular hemorrhage, mass effect, obstructive hydrocephalus and vasogenic edema on brain CT.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Chest/Lung; Brain Input: CXR: at least one frontal AP or PA view, with up to three images total and lateral views supported. CTB: non-contrast axial brain CT, up to 1,000 images, slice thickness <=5 mm, using a brain reconstruction kernel or similar.
  • Who uses it?Intended users: Radiologists and other qualified healthcare professionals interpreting adult chest radiographs and non-contrast brain CT.
  • What does the software produce?Output: Study-level abnormality notifications and prioritization information for the listed CXR and brain-CT findings; final interpretation remains with the clinician.
  • What is its most important limitation?Key limitation: Cleared adult use is limited to the listed findings and input requirements. Notifications do not replace image interpretation, are not a standalone clinical decision, and should not be treated as a negative rule-out result.

Clinical takeaway. Clinical role: Triage and prioritization of adult CXR and non-contrast brain CT studies for specified suspected findings, including pneumoperitoneum, pleural effusion, pneumothorax and tension pneumothorax on CXR, and acute extra-axial hemorrhage, subarachnoid hemorrhage, intra-axial hemorrhage, intraventricular hemorrhage, mass effect, obstructive hydrocephalus and vasogenic edema on brain CT.

Evidence takeaway. Evidence from the reviewed source record: The reviewed FDA summary establishes the multi-modality intended-use and input boundaries for Annalise Enterprise 3.10+ but does not provide a single consolidated performance metric suitable for this dossier.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Triage and prioritization of adult CXR and non-contrast brain CT studies for specified suspected findings, including pneumoperitoneum, pleural effusion, pneumothorax and tension pneumothorax on CXR, and acute extra-axial hemorrhage, subarachnoid hemorrhage, intra-axial hemorrhage, intraventricular hemorrhage, mass effect, obstructive hydrocephalus and vasogenic edema on brain CT.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Notification-only study triage and prioritization; the product is not a standalone clinical decision tool or a rule-out system.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
CXR: at least one frontal AP or PA view, with up to three images total and lateral views supported. CTB: non-contrast axial brain CT, up to 1,000 images, slice thickness <=5 mm, using a brain reconstruction kernel or similar.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Study-level abnormality notifications and prioritization information for the listed CXR and brain-CT findings; final interpretation remains with the clinician.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Adult hospital and outpatient imaging workflows using chest radiography and non-contrast brain CT.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Radiologists and other qualified healthcare professionals interpreting adult chest radiographs and non-contrast brain CT.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
Cleared adult use is limited to the listed findings and input requirements. Notifications do not replace image interpretation, are not a standalone clinical decision, and should not be treated as a negative rule-out result.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
The reviewed FDA summary establishes the multi-modality intended-use and input boundaries for Annalise Enterprise 3.10+ but does not provide a single consolidated performance metric suitable for this dossier.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The reviewed FDA summary establishes the multi-modality intended-use and input boundaries for Annalise Enterprise 3.10+ but does not provide a single consolidated performance metric suitable for this dossier.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Op 0.250: 96.2% (92.4,99.0), Op 0.300: 94.3% (89.5,98.1) , Op 0.350: 92.4% (86.7,97.1) , Op 0.400: 91.4% (85.7,96.2), Op 0.450: 87.6% (81.0,93.3)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
Op 0.225: 87.9% (83.2,92.1), Op 0.250: 90.5% (86.3,94.2), Op 0.300: 93.7% (90.0,96.8), Op 0.350: 95.8% (92.6,98.4), Op 0.400: 98.4% (96.3,100.0)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Annalise Enterprise 3.10+ multi-modality validation

  • DesignRegulatory software and performance evidence described in the FDA 510(k) summary
  • PopulationAdult chest radiographs and non-contrast brain CT studies within the listed input requirements
  • Scopeexact submission
  • Tested versionAnnalise Enterprise 3.10+
  • IndependenceSponsor or vendor study

K250831

The reviewed public summary was used for indication, input and workflow boundaries; no consolidated disease-performance value is promoted here.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: CXR: at least one frontal AP or PA view, with up to three images total and lateral views supported. CTB: non-contrast axial brain CT, up to 1,000 images, slice thickness <=5 mm, using a brain reconstruction kernel or similar.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K250831: Annalise Enterprise

  2. Routing

    Source context, not route validation: The submission describes study-level integration with the radiology worklist/PACS workflow for notification and prioritization; exact local routing and reader configuration require site confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K250831: Annalise Enterprise

  3. AI processing

    Source context, not route validation: Annalise Enterprise is described in the FDA submission as software integrated into the imaging workflow; the exact site hosting model for this submission is not established in the public summary.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K250831: Annalise Enterprise

  4. Returned objects

    Source context, not route validation: Study-level abnormality notifications and prioritization information for the listed CXR and brain-CT findings; final interpretation remains with the clinician.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K250831: Annalise Enterprise

  5. Viewer/worklist/report

    Unresolved route: Study-level abnormality notifications and prioritization information for the listed CXR and brain-CT findings; final interpretation remains with the clinician.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K250831: Annalise Enterprise

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Annalise Enterprise is described in the FDA submission as software integrated into the imaging workflow; the exact site hosting model for this submission is not established in the public summary.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
The submission describes study-level integration with the radiology worklist/PACS workflow for notification and prioritization; exact local routing and reader configuration require site confirmation.
  • Exact FDA submission
  • Checked 2026-09-07
Security
The family administration guide describes protected data transfer and configurable retention/deletion behavior for Annalise Enterprise.
  • Product family
  • Checked 2026-09-06

This is family context only, not an exact-release certification, penetration-test result or site-specific security assessment for K250831.

Notification and worklist prioritization

The cleared product returns study-level notifications for listed findings rather than image markup or a standalone clinical decision.

exact submission · checked 2026-09-07

PACS/RIS workflow administration

The official Comprehensive Care page describes PACS/RIS workflow integration, and the Annalise administration documentation describes configurable PACS/RIS interfaces for the family.

product family · checked 2026-09-07

Connector availability, hosting and configuration for K250831 require vendor/site confirmation; the administration PDF was reviewed via web-rendered/cached fulltext after a direct-fetch 403.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K250831
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

The submission is multi-modality. The input fact preserves the exact CXR and CT requirements rather than collapsing the product to one modality.

Anatomy
Chest/Lung; Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-04-23
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-07Last searched
24Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is not a full-paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor technical documentation, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public price or quote for K250831 was reviewed.

  • Pricing model: Not verified - checked 2026-09-07 - Exact FDA submission

    License, per-study, subscription and implementation terms were not established.

  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Annalise Enterprise reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Harrison.ai's 2024-08-02 release announces NTAP for Annalise Obstructive Hydrocephalus; it is not shown to be this entry. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-07 - Exact FDA submission

    The reviewed guides describe administration but do not establish site-specific training deliverables for K250831.

  • Monitoring: Not verified - checked 2026-09-07 - Exact FDA submission

    No exact-release clinical performance monitoring or drift program was established.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K250831: Annalise Enterprise

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, purpose, clinicalUse, modality, anatomy, workflowRole, intendedUsers, careSetting, input, output, limitations, integration, deployment, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Harrison.ai Comprehensive Care (CXR - pneumoperitoneum) model card (K250831)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Harrison.ai Comprehensive Care: chest X-ray and non-contrast head CT

    Harrison.ai / Annalise.ai - Accessed 2026-09-07

    Scope: productFamilyContext, clinicalUse, implementationCapabilities, integration

  8. Annalise Enterprise Administration Guide 8

    Annalise.ai - Accessed 2026-09-06

    Scope: implementationCapabilities, integration, security

Research history

  1. K250831 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K233582

Rapid

iSchema View Inc.

Authorized purpose: Rapid is image-viewing, processing, and analysis software for DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data, including perfusion maps and acute-stroke selection support under the labeled occlusion and imaging criteria.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain, cerebral vasculature, and perfusion regions
Decision
2024-04-22
FDA-cleared K233512

Rapid (6.0)

iSchemaView, Inc.

Authorized purpose: Rapid Platform v6.0 is image-processing software for trained professionals that views, processes, and analyzes DICOM images from CT and MRI. It supports functional and dynamic datasets including CT perfusion, CT angiography, diffusion-weighted MRI, and dynamic contrast-enhanced CT or MRI, with maps and measurements for tissue perfusion, diffusion, and blood volume. Rapid CT-Perfusion and Rapid MR-Perfusion may aid physicians in selecting acute stroke patients with known occlusion of the intracranial internal carotid artery or proximal middle cerebral artery for endovascular thrombectomy, subject to the labeled imaging criteria, clinical requirements, and exclusions.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain and intracranial vessels represented in CT perfusion, CTA, and MRI; tissue perfusion, diffusion, and contrast dynamics
Decision
2024-01-16
FDA-cleared K213165

Rapid

iSchema View Inc.

Authorized purpose: Rapid processes CT, CTP, CTA, diffusion MRI, and dynamic-contrast MRI for stroke viewing, perfusion, volumetry, mismatch, and large-vessel-density support for trained professionals.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2022-02-08
FDA-cleared K200750

Neuro.Al Algorithm

TeraRecon, Inc.

Authorized purpose: Neuro.Al Algorithm processes static, functional, dynamic, and derived CT or MR images to support brain perfusion analysis, tissue blood-volume and parametric-map review, ventricular visualization, and DICOM return to clinical viewers for trained professional interpretation.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain and intracranial perfusion regions
Decision
2020-11-06

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history